Nerandomilast is a preferential inhibitor of phosphodiesterase 4B (PDE4B) with antifibrotic and immunomodulatory effects, a ...

Takeda is organized around five core businesses: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for over 80% of revenue. It also has a developing ...